Chinese General Practice ›› 2024, Vol. 27 ›› Issue (20): 2476-2482.DOI: 10.12114/j.issn.1007-9572.2023.0837
• Original Research • Previous Articles Next Articles
Received:
2023-10-20
Revised:
2024-03-03
Published:
2024-07-15
Online:
2024-04-08
Contact:
CHI Gefu
通讯作者:
迟戈夫
作者简介:
作者贡献:
侯娜娜负责提出研究思路,设计研究方案,数据的收集,统计学分析,撰写论文并对论文整体负责;冯金章、刘锁红、冯俊芳负责论文修订;薛小艳、尹娜负责选取研究对象,数据收集;迟戈夫负责论文的质量控制与审查,对论文整体负责,监督管理。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0837
组别 | 例数 | 性别[例(%)] | 年龄( | WC ( | BMI ( | SBP ( | DBP ( | |
---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||
非MAFLD组 | 1 343 | 626(46.6) | 717(53.4) | 45.4±11.4 | 83.56±9.38 | 23.4±2.9 | 123±16 | 77±11 |
MAFLD组 | 945 | 688(72.8) | 257(27.2) | 48.1±10.6 | 94.70±9.16 | 27.1±3.1 | 132±16 | 84±11 |
检验统计量值 | 155.651a | 5.793 | 28.361 | 29.531 | 12.766 | 15.045 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | ALT[M(P25,P75),U/L] | AST[M(P25,P75),U/L] | ALP ( | GGT[M(P25,P75),U/L] | Scr( | SUA( | TC( | |
非MAFLD组 | 17.0(12.7,24.2) | 16.5(14.2,20.0) | 61.03±17.41 | 20.00(14.40,31.70) | 68.37±13.79 | 323.67±84.88 | 4.80±0.98 | |
MAFLD组 | 25.8(18.3,37.0) | 18.7(15.6,23.2) | 67.38±18.36 | 35.40(23.30,53.10) | 73.17±14.62 | 377.99±92.30 | 4.97±1.00 | |
检验统计量值 | -17.238b | -9.916b | 8.401 | -18.463b | 7.999 | 14.534 | 4.163 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | TG[M(P25,P75),mmol/L] | HDL-C( | LDL-C( | FBG[M(P25,P75),mmol/L] | HbA1c[M(P25,P75),%] | Hcy[M(P25,P75),μmol/L] | SUA/Cr[M(P25,P75)] | |
非MAFLD组 | 1.19(0.86,1.65) | 1.32±0.29 | 3.08±0.80 | 4.70(4.40,5.06) | 5.50(5.30,5.70) | 12.17(9.83,5.53) | 4.68(4.02,5.53) | |
MAFLD组 | 1.85(1.33,2.65) | 1.13±0.22 | 3.36±0.82 | 4.99(4.60,5.63) | 5.70(5.50,6.10) | 13.22(10.79,16.93) | 5.11(4.36,6.13) | |
检验统计量值 | -18.864b | -18.750 | 8.070 | -12.288b | -12.871b | -6.006b | -8.728b | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of general clinical data between MAFLD and non-MAFLD groups
组别 | 例数 | 性别[例(%)] | 年龄( | WC ( | BMI ( | SBP ( | DBP ( | |
---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||
非MAFLD组 | 1 343 | 626(46.6) | 717(53.4) | 45.4±11.4 | 83.56±9.38 | 23.4±2.9 | 123±16 | 77±11 |
MAFLD组 | 945 | 688(72.8) | 257(27.2) | 48.1±10.6 | 94.70±9.16 | 27.1±3.1 | 132±16 | 84±11 |
检验统计量值 | 155.651a | 5.793 | 28.361 | 29.531 | 12.766 | 15.045 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | ALT[M(P25,P75),U/L] | AST[M(P25,P75),U/L] | ALP ( | GGT[M(P25,P75),U/L] | Scr( | SUA( | TC( | |
非MAFLD组 | 17.0(12.7,24.2) | 16.5(14.2,20.0) | 61.03±17.41 | 20.00(14.40,31.70) | 68.37±13.79 | 323.67±84.88 | 4.80±0.98 | |
MAFLD组 | 25.8(18.3,37.0) | 18.7(15.6,23.2) | 67.38±18.36 | 35.40(23.30,53.10) | 73.17±14.62 | 377.99±92.30 | 4.97±1.00 | |
检验统计量值 | -17.238b | -9.916b | 8.401 | -18.463b | 7.999 | 14.534 | 4.163 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | TG[M(P25,P75),mmol/L] | HDL-C( | LDL-C( | FBG[M(P25,P75),mmol/L] | HbA1c[M(P25,P75),%] | Hcy[M(P25,P75),μmol/L] | SUA/Cr[M(P25,P75)] | |
非MAFLD组 | 1.19(0.86,1.65) | 1.32±0.29 | 3.08±0.80 | 4.70(4.40,5.06) | 5.50(5.30,5.70) | 12.17(9.83,5.53) | 4.68(4.02,5.53) | |
MAFLD组 | 1.85(1.33,2.65) | 1.13±0.22 | 3.36±0.82 | 4.99(4.60,5.63) | 5.70(5.50,6.10) | 13.22(10.79,16.93) | 5.11(4.36,6.13) | |
检验统计量值 | -18.864b | -18.750 | 8.070 | -12.288b | -12.871b | -6.006b | -8.728b | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 性别[例(%)] | 年龄( | WC ( | BMI ( | SBP ( | DBP ( | |
---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||
Q1组 | 574 | 298(22.7) | 276(28.3) | 48.7±10.9 | 85.36±10.41 | 24.0±3.2 | 126±17 | 79±11 |
Q2组 | 573 | 341(26.0) | 232(23.8) | 46.7±10.8c | 87.36±10.37c | 24.7±3.4c | 127±16 | 80±12 |
Q3组 | 570 | 341(26.0) | 229(23.5) | 46.4±11.2c | 88.55±10.00c | 25.0±3.3c | 127±16 | 80±12 |
Q4组 | 571 | 334(25.4) | 237(24.3) | 44.2±11.1cd | 91.38±11.45cde | 26.0±3.7cde | 127±17 | 81±12c |
检验统计量值 | 4.714a | 15.468b | 32.454b | 34.756b | 0.747b | 2.889b | ||
P值 | 0.030 | <0.001 | <0.001 | <0.001 | 0.524 | 0.034 | ||
组别 | ALT [M(P25,P75),U/L] | AST [M(P25,P75),U/L] | ALP ( | GGT [M(P25,P75),U/L] | Scr ( | SUA ( | TC ( | |
Q1组 | 16.4(12.4,23.5) | 16.6(14.1,20.0) | 62.08±17.90 | 20.25(13.90,33.15) | 74.97±15.70 | 267.24±64.05 | 4.71±0.96 | |
Q2组 | 18.8(13.5,26.8)c | 16.9(14.3,20.8) | 62.92±18.60 | 23.30(15.65,39.35)c | 72.24±13.53 | 324.83±63.21c | 4.75±0.99 | |
Q3组 | 21.5(15.2,29.7)cd | 17.8(15.2,21.7)cd | 64.61±17.22 | 26.55(18.25,44.28)cd | 69.93±13.25cd | 367.22±70.07cd | 4.93±0.96cd | |
Q4组 | 25.5(17.5,35.9)cde | 18.4(15.2,23.1)cd | 65.02±18.44c | 33.60(21.30,53.50)cde | 64.24±12.43cde | 425.66±86.05cde | 5.10±1.01cde | |
检验统计量值 | 168.886 | 46.385 | 3.386b | 150.397 | 158.306 | 927.158 | 18.853b | |
P值 | <0.001 | <0.001 | 0.017 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | TG [M(P25,P75),mmol/L] | HDL-C ( | LDL-C ( | FBG [M(P25,P75),mmol/L] | HbA1c [M(P25,P75),%] | Hcy [M(P25,P75),μmol/L] | ||
Q1组 | 1.20(0.87,1.69) | 1.30±0.30 | 3.17±0.86 | 4.82(4.50,5.23) | 5.60(5.40,5.80) | 12.66(10.15,16.90) | ||
Q2组 | 1.32(0.94,1.91)c | 1.25±0.28c | 3.16±0.82 | 4.79(4.49,5.21) | 5.60(5.40,5.80) | 12.48(9.98,15.72) | ||
Q3组 | 1.48(1.06,2.19)cd | 1.23±0.27c | 3.23±0.81 | 4.75(4.45,5.19) | 5.60(5.40,5.90) | 12.73(10.20,15.79) | ||
Q4组 | 1.70(1.19,2.54)cde | 1.18±0.26cde | 3.20±0.80 | 4.82(4.44,5.43) | 5.60(5.40,5.90)c | 12.34(10.07,16.07) | ||
检验统计量值 | 138.296 | 60.732b | 0.967b | 2.889 | 9.775 | 1.670 | ||
P值 | <0.001 | <0.001 | 0.407 | 0.409 | 0.021 | 0.644 |
Table 2 Comparison of general clinical data in SUA/Cr quartile groupings
组别 | 例数 | 性别[例(%)] | 年龄( | WC ( | BMI ( | SBP ( | DBP ( | |
---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||
Q1组 | 574 | 298(22.7) | 276(28.3) | 48.7±10.9 | 85.36±10.41 | 24.0±3.2 | 126±17 | 79±11 |
Q2组 | 573 | 341(26.0) | 232(23.8) | 46.7±10.8c | 87.36±10.37c | 24.7±3.4c | 127±16 | 80±12 |
Q3组 | 570 | 341(26.0) | 229(23.5) | 46.4±11.2c | 88.55±10.00c | 25.0±3.3c | 127±16 | 80±12 |
Q4组 | 571 | 334(25.4) | 237(24.3) | 44.2±11.1cd | 91.38±11.45cde | 26.0±3.7cde | 127±17 | 81±12c |
检验统计量值 | 4.714a | 15.468b | 32.454b | 34.756b | 0.747b | 2.889b | ||
P值 | 0.030 | <0.001 | <0.001 | <0.001 | 0.524 | 0.034 | ||
组别 | ALT [M(P25,P75),U/L] | AST [M(P25,P75),U/L] | ALP ( | GGT [M(P25,P75),U/L] | Scr ( | SUA ( | TC ( | |
Q1组 | 16.4(12.4,23.5) | 16.6(14.1,20.0) | 62.08±17.90 | 20.25(13.90,33.15) | 74.97±15.70 | 267.24±64.05 | 4.71±0.96 | |
Q2组 | 18.8(13.5,26.8)c | 16.9(14.3,20.8) | 62.92±18.60 | 23.30(15.65,39.35)c | 72.24±13.53 | 324.83±63.21c | 4.75±0.99 | |
Q3组 | 21.5(15.2,29.7)cd | 17.8(15.2,21.7)cd | 64.61±17.22 | 26.55(18.25,44.28)cd | 69.93±13.25cd | 367.22±70.07cd | 4.93±0.96cd | |
Q4组 | 25.5(17.5,35.9)cde | 18.4(15.2,23.1)cd | 65.02±18.44c | 33.60(21.30,53.50)cde | 64.24±12.43cde | 425.66±86.05cde | 5.10±1.01cde | |
检验统计量值 | 168.886 | 46.385 | 3.386b | 150.397 | 158.306 | 927.158 | 18.853b | |
P值 | <0.001 | <0.001 | 0.017 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | TG [M(P25,P75),mmol/L] | HDL-C ( | LDL-C ( | FBG [M(P25,P75),mmol/L] | HbA1c [M(P25,P75),%] | Hcy [M(P25,P75),μmol/L] | ||
Q1组 | 1.20(0.87,1.69) | 1.30±0.30 | 3.17±0.86 | 4.82(4.50,5.23) | 5.60(5.40,5.80) | 12.66(10.15,16.90) | ||
Q2组 | 1.32(0.94,1.91)c | 1.25±0.28c | 3.16±0.82 | 4.79(4.49,5.21) | 5.60(5.40,5.80) | 12.48(9.98,15.72) | ||
Q3组 | 1.48(1.06,2.19)cd | 1.23±0.27c | 3.23±0.81 | 4.75(4.45,5.19) | 5.60(5.40,5.90) | 12.73(10.20,15.79) | ||
Q4组 | 1.70(1.19,2.54)cde | 1.18±0.26cde | 3.20±0.80 | 4.82(4.44,5.43) | 5.60(5.40,5.90)c | 12.34(10.07,16.07) | ||
检验统计量值 | 138.296 | 60.732b | 0.967b | 2.889 | 9.775 | 1.670 | ||
P值 | <0.001 | <0.001 | 0.407 | 0.409 | 0.021 | 0.644 |
项目 | MAFLD组 | 非MAFLD组 | ||
---|---|---|---|---|
rs值 | P值 | rs值 | P值 | |
性别 | 0.063 | 0.055 | -0.030 | 0.264 |
年龄 | -0.217 | <0.001 | -0.123 | <0.001 |
WC | 0.084 | 0.010 | 0.150 | <0.001 |
BMI | 0.074 | 0.023 | 0.159 | <0.001 |
SBP | -0.001 | 0.985 | -0.011 | 0.678 |
DBP | 0.012 | 0.714 | -0.013 | 0.635 |
ALT | 0.252 | <0.001 | 0.207 | <0.001 |
AST | 0.147 | <0.001 | 0.074 | 0.007 |
ALP | 0.019 | 0.557 | 0.056 | 0.041 |
GGT | 0.212 | <0.001 | 0.216 | <0.001 |
Scr | -0.381 | <0.001 | -0.259 | <0.001 |
SUA | 0.648 | <0.001 | 0.664 | <0.001 |
TC | 0.191 | <0.001 | 0.121 | <0.001 |
TG | 0.165 | <0.001 | 0.207 | <0.001 |
HDL-C | -0.050 | 0.121 | -0.142 | <0.001 |
LDL-C | 0.023 | 0.489 | -0.018 | 0.520 |
FBG | -0.050 | 0.122 | -0.061 | 0.024 |
HbA1c | -0.022 | 0.490 | 0.017 | 0.533 |
Hcy | -0.083 | 0.011 | -0.010 | 0.726 |
Table 3 Correlation analysis of SUA/Cr with clinical data of study participants
项目 | MAFLD组 | 非MAFLD组 | ||
---|---|---|---|---|
rs值 | P值 | rs值 | P值 | |
性别 | 0.063 | 0.055 | -0.030 | 0.264 |
年龄 | -0.217 | <0.001 | -0.123 | <0.001 |
WC | 0.084 | 0.010 | 0.150 | <0.001 |
BMI | 0.074 | 0.023 | 0.159 | <0.001 |
SBP | -0.001 | 0.985 | -0.011 | 0.678 |
DBP | 0.012 | 0.714 | -0.013 | 0.635 |
ALT | 0.252 | <0.001 | 0.207 | <0.001 |
AST | 0.147 | <0.001 | 0.074 | 0.007 |
ALP | 0.019 | 0.557 | 0.056 | 0.041 |
GGT | 0.212 | <0.001 | 0.216 | <0.001 |
Scr | -0.381 | <0.001 | -0.259 | <0.001 |
SUA | 0.648 | <0.001 | 0.664 | <0.001 |
TC | 0.191 | <0.001 | 0.121 | <0.001 |
TG | 0.165 | <0.001 | 0.207 | <0.001 |
HDL-C | -0.050 | 0.121 | -0.142 | <0.001 |
LDL-C | 0.023 | 0.489 | -0.018 | 0.520 |
FBG | -0.050 | 0.122 | -0.061 | 0.024 |
HbA1c | -0.022 | 0.490 | 0.017 | 0.533 |
Hcy | -0.083 | 0.011 | -0.010 | 0.726 |
变量 | B | SE | Waldχ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
WC | 0.034 | 0.009 | 13.305 | <0.001 | 1.034(1.016~1.053) |
BMI | 0.292 | 0.029 | 101.876 | <0.001 | 1.340(1.266~1.418) |
GGT | 0.006 | 0.002 | 14.117 | <0.001 | 1.006(1.003~1.010) |
SUA | 0.002 | 0.001 | 6.651 | 0.010 | 1.002(1.000~1.003) |
TG | 0.277 | 0.057 | 24.051 | <0.001 | 1.319(1.181~1.474) |
HDL-C | -1.097 | 0.248 | 19.486 | <0.001 | 0.334(0.205~0.543) |
HbA1c | 0.299 | 0.066 | 20.301 | <0.001 | 1.348(1.184~1.536) |
Table 4 Multivariate Logistic regression analysis of factors affecting the prevalence of MAFLD
变量 | B | SE | Waldχ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
WC | 0.034 | 0.009 | 13.305 | <0.001 | 1.034(1.016~1.053) |
BMI | 0.292 | 0.029 | 101.876 | <0.001 | 1.340(1.266~1.418) |
GGT | 0.006 | 0.002 | 14.117 | <0.001 | 1.006(1.003~1.010) |
SUA | 0.002 | 0.001 | 6.651 | 0.010 | 1.002(1.000~1.003) |
TG | 0.277 | 0.057 | 24.051 | <0.001 | 1.319(1.181~1.474) |
HDL-C | -1.097 | 0.248 | 19.486 | <0.001 | 0.334(0.205~0.543) |
HbA1c | 0.299 | 0.066 | 20.301 | <0.001 | 1.348(1.184~1.536) |
组别 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
Q1组 | 1.000 | — | 1.000 | — | 1.000 | — |
Q2组 | 1.339(1.047~1.712) | 0.020 | 1.140(0.847~1.533) | 0.388 | 1.116(0.816~1.527) | 0.491 |
Q3组 | 1.769(1.387~2.255) | <0.001 | 1.452(1.084~1.945) | 0.012 | 1.386(1.009~1.904) | 0.044 |
Q4组 | 2.689(2.111~3.426) | <0.001 | 1.935(1.435~2.610) | <0.001 | 1.734(1.220~2.465) | 0.002 |
Table 5 Multivariate Logistic regression analysis of the risk of prevalence of MAFLD in subgroups with different SUA/Cr levels
组别 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
Q1组 | 1.000 | — | 1.000 | — | 1.000 | — |
Q2组 | 1.339(1.047~1.712) | 0.020 | 1.140(0.847~1.533) | 0.388 | 1.116(0.816~1.527) | 0.491 |
Q3组 | 1.769(1.387~2.255) | <0.001 | 1.452(1.084~1.945) | 0.012 | 1.386(1.009~1.904) | 0.044 |
Q4组 | 2.689(2.111~3.426) | <0.001 | 1.935(1.435~2.610) | <0.001 | 1.734(1.220~2.465) | 0.002 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
秦迁,闫肃,杨阳,等. 血尿酸轨迹与代谢相关脂肪性肝病的相关性纵向数据研究[J]. 中国预防医学杂志,2023,24(8):814-819. DOI:10.16506/j.1009-6639.2023.08.011.
|
[7] |
|
[8] |
|
[9] |
|
[10] |
郑盼盼,赵维丽,胡庆山,等. 2型糖尿病合并代谢相关脂肪性肝病影响因素的研究[J]. 中国糖尿病杂志,2023,31(2):99-103. DOI:10.3969/j.issn.1006-6187.2023.02.004.
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||